A real-world study of the immunogenicity of inactivated SARS-CoV-2 vaccine

doi:10.19871/j.cnki.xfcrbzz.2023.03.008

Abstract

Abstract: Objective To study the immunogenicity and related factors of the 3 doses inactivated SARS-CoV-2 vaccine. Method People who received 3 doses of inactivated SARS-CoV-2 vaccine in Nanchang Ninth Hospital from December 2020 to October 2021 were selected, At 3 weeks after the first dose, 4 weeks,16 weeks and 32 weeks after the second dose, and 4 weeks after the third dose, the blood neutralizing antibody, IgG and IgM antibody were detected respectively. Result A total of 874 participants were enrolled, including 316 males and 558 females. The positive rates of neutralizing antibody were 26.2%, 86.6%, 74.2%, 78.2% and 98.1% respectively at 3 weeks after the first dose, 4 weeks, 16 weeks, 32 weeks after the second dose and 4 weeks after the third dose;The positive rates of IgG antibody were 25.1%, 93.2%, 59.3%, 45.7% and 96.8% respectively. The quantitation of neutralizing antibody and IgG antibody at 4,16,32 weeks after the second dose and 4 weeks after the third dose were significantly higher than those at 3 weeks after the first dose (P<0.0001); 16,32 weeks after the second dose were significantly lower than 4 weeks after the second dose (P<0.0001); 4 weeks after the third dose were significantly higher than 4 weeks after the second dose (P<0.0001). Conclusion Two doses of the inactivated SARS-CoV-2 vaccine can produce a large number of neutralizing and IgG antibodies to play the immune effect, and the addition of the third dose of booster can significantly increase the peak value of both.

Key words: Severe acute respiratory syndrome coronavirus 2, Vaccine, Neutralizing antibody, Immuno globulin G, Immunogenicity, Real-world study

CLC Number:

R186

Peng Xuping, Zhang Zhicheng, Zhang Dan, Rao Jianfeng, Wang Li, Li Xue, Ju Weihua, Tu Xianglin, Wang Shumei, Luo Daya, Liu Zhuoqi, Huang Yanxia, Ao Qinfang, Zhou Yalan, Chen Hongyi. A real-world study of the immunogenicity of inactivated SARS-CoV-2 vaccine[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(3): 39-43.

References

[1] WORLD HEALTH ORGANIZATION.Tracking SARS-CoV-2 variants[EB/OL].[2021-12-09].https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
[2] 康庄, 唐梅. 新型冠状病毒疫苗的研发进展及分析[J]. 生物医学工程学杂志, 2020, 37(3):373-379.
[3] WILDER-SMITH A, MULHOLLAND K.Effectiveness of an Inactivated SARS-CoV-2 Vaccine[J]. N Engl J Med, 2021, 385(10):946-948.
[4] ZENG G, WU Q, PAN H, et al.Immunogenicity and safety of a third dose of CoronaVac,and immune persistence of a two-dose schedule,in healthy adults:interim results from two single-centre, double-blind,randomised,placebo-controlled phase 2 clinical trials[J]. Lancet Infect Dis, 2022, 22(4):483-495.
[5] DONG Y, DAI T, WEI Y, et al.A systematic review of SARS‐CoV‐2 vaccine candidates[J].Signal Transduct Target Ther, 2020, 5(1):237.
[6] 李倩,卢洪洲.新型冠状病毒疫苗研究最新进展[J/CD].新发传染病电子杂志, 2020, 5(4):268-273.
[7] XIA S, ZHANG Y, WANG Y, et al.Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,BBIBP-CorV:a randomised,double-blind,placebo-controlled,phase1/2 trial[J]. Lancet Infect Dis, 2021, 21(1):39-51.
[8] ZHANG Y, ZENG G, PAN H, et al.Safety,tolerability,and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years:a randomized,double-blind,placebo-controlled,phase 1/2clinical trial[J].Lancet Infect Dis, 2021, 21(2):181-192.
[9] 朱瑶, 韦意娜, 孙畅, 等.新型冠状病毒肺炎疫苗研究进展[J].预防医学, 2021, 33(2):143-148.
[10] 国药集团中国生物武汉生物制品研究所.国药集团中国生物武汉生物制品研究所新冠灭活疫苗Ⅲ期临床试验期中分析数据发布[EB/OL].[2021-02-24]. http://www.wibp.com.cn/Chs/Detail.aspx?Id=14669.
[11] DAGAN N, BARDA N, KEPTEN E, et al.BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting[J]. N Engl J Med, 2021, 384(15):1412-1423.
[12] FURLOW B.Immunocompromised patients in the USA and UK should receive third dose of COVID-19 vaccine[J].Lancet Rheumatol, 2021, 3(11):e756.
[13] BAR-ON YM, GOLDBERG Y, MANDEL M, et al.Protection of BNT162b2 vaccine booster against Covid-19 in Israel[J]. N Engl J Med, 2021, 385(15):1393-1400.
[14] AI J, ZHANG Y, ZHANG H, et al.Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination:interim results from a prospective open-label study[J].Emerg Microbes Infect, 2022, 11(1):639-647.
[15] FERDINANDS JM, RAO S, DIXON BE, et al.Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance — VISION Network, 10 states, August 2021-January 2022[J]. MMWR Morb Mortal Wkly Rep, 2022, 71(7): 255-263.
[16] MAGEN O, WAXMAN JG, MAKOV-ASSIF M, et al.Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting[J]. N Engl J Med, 2022, 386(17):1603-1614.
[17] WANG J, DENG C, LIU M, et al.A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain[J]. Nat Commun, 2022, 13(1):6866.
[18] BAR-ON YM, GOLDBERG Y, MANDEL M, et al.Protection by a Fourth Dose of BNT162b2 against Omicron in Israel[J]. N Engl J Med, 2022, 386(18):1712-1720.
[19] COHEN MJ, OSTER Y, MOSES AE, et al.Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel[J]. JAMA Netw Open, 2022, 5(8):e2224657.
[20] TAKAHASHI T, IWASAKI A.Sex differences in immune responses[J]. Science, 2021, 371(6527):347-348.
[21] AI J, WANG J, LIU D, et al.Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101):A Multicenter Study[J].Clin Gastroenterol Hepatol, 2022, 20(7):1516-1524.